IDEAYA Biosciences, Inc. - Common Stock (IDYA)

Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38.

IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates.

IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the second quarter of 2024.

Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.

IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a favorable adverse event profile, highlighting IDE397's potential as a monotherapy.

The company is working on a treatment for cancers tied to a genetic alteration called MTAP deletion.

IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the first quarter of 2024.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Ideaya stock is getting hit hard following a recent press release from the company.